Literature DB >> 12627412

Issues in designing flexible trials.

Martin Posch1, Peter Bauer, Werner Brannath.   

Abstract

We outline the general framework of adaptive combination tests and discuss their relationship to flexible group sequential designs. An important field of applications is sample size reassessment. We discuss reassessment rules based on conditional power arguments using either the observed or the prefixed effect size. These rules tend to lead to large expected sample sizes for small actual effects. However, the application of a maximal bound for the second stage sample size leads to more favourable properties. Additionally, we consider an optimized reassessment rule in terms of expected sample sizes. Since the adaptive design does not use the classical test statistics for some types of sample size reassessments, the adaptive test may reject the null hypothesis while the classical one-sample test does not. We characterize sample size reassessment rules, where such inconsistencies are avoided. Finally, the extension of flexibility to the number of stages is explored. In the first interim analysis a second interim analysis is only planned if the chance to achieve a decision there is high. This leads to savings in the average number of interim analysis performed, without paying a noticeable price in terms of expected sample size. Copyright 2003 John Wiley & Sons, Ltd.

Mesh:

Year:  2003        PMID: 12627412     DOI: 10.1002/sim.1455

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  11 in total

1.  Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls.

Authors:  Peter Bauer; Frank Bretz; Vladimir Dragalin; Franz König; Gernot Wassmer
Journal:  Stat Med       Date:  2015-03-16       Impact factor: 2.373

2.  Interim Monitoring for Futility in Clinical Trials with Two Co-primary Endpoints Using Prediction.

Authors:  Koko Asakura; Scott R Evans; Toshimitsu Hamasaki
Journal:  Stat Biopharm Res       Date:  2019-11-04       Impact factor: 1.452

3.  Options and Considerations for Adaptive Laboratory Experiments.

Authors:  Lai Wei; David Jarjoura
Journal:  Stat Biosci       Date:  2014-11-25

4.  Adaptive Budgets in Clinical Trials.

Authors:  Martin Posch; Peter Bauer
Journal:  Stat Biopharm Res       Date:  2013-04-04       Impact factor: 1.452

5.  Sample size reassessment for a two-stage design controlling the false discovery rate.

Authors:  Sonja Zehetmayer; Alexandra C Graf; Martin Posch
Journal:  Stat Appl Genet Mol Biol       Date:  2015-11

6.  Adaptive graph-based multiple testing procedures.

Authors:  Florian Klinglmueller; Martin Posch; Franz Koenig
Journal:  Pharm Stat       Date:  2014-10-16       Impact factor: 1.894

7.  Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit.

Authors:  Patrick Royston; Friederike M-S Barthel; Mahesh Kb Parmar; Babak Choodari-Oskooei; Valerie Isham
Journal:  Trials       Date:  2011-03-18       Impact factor: 2.279

8.  Maximum type I error rate inflation from sample size reassessment when investigators are blind to treatment labels.

Authors:  Magdalena Żebrowska; Martin Posch; Dominic Magirr
Journal:  Stat Med       Date:  2015-12-23       Impact factor: 2.373

9.  Adaptive designs in clinical trials: from scientific advice to marketing authorisation to the European Medicine Agency.

Authors:  Olivier Collignon; Franz Koenig; Armin Koch; Robert James Hemmings; Frank Pétavy; Agnès Saint-Raymond; Marisa Papaluca-Amati; Martin Posch
Journal:  Trials       Date:  2018-11-20       Impact factor: 2.279

10.  Estimation after blinded sample size reassessment.

Authors:  Martin Posch; Florian Klinglmueller; Franz König; Frank Miller
Journal:  Stat Methods Med Res       Date:  2016-10-02       Impact factor: 3.021

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.